BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32089334)

  • 1. Radical hysterectomy is not associated with a survival benefit for patients with stage II endometrial carcinoma.
    Nasioudis D; Sakamuri S; Ko EM; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Latif NA
    Gynecol Oncol; 2020 May; 157(2):335-339. PubMed ID: 32089334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
    Nasioudis D; Byrne M; Ko EM; Giuntoli RL; Haggerty AF; Cory L; Kim SH; Morgan MA; Latif NA
    Gynecol Oncol; 2021 Jun; 161(3):705-709. PubMed ID: 33771397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of minimally invasive surgery for patients with endometrial carcinoma involving the cervix.
    Nasioudis D; Frey MK; Chapman-Davis E; Caputo TA; Holcomb K
    Int J Gynecol Cancer; 2020 May; 30(5):619-625. PubMed ID: 32276935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a benefit of performing an omentectomy for clinical stage I high-grade endometrial carcinoma?
    Nasioudis D; Heyward Q; Gysler S; Giuntoli RL; Cory L; Kim S; Morgan MA; Haggerty AF; Ko EM; Latif NA
    Surg Oncol; 2021 Jun; 37():101534. PubMed ID: 33667893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy.
    Reshko LB; Gaskins JT; Dryden SM; Metzinger DS; Todd SL; Eldredge-Hindy HB; Silva SR
    Int J Gynecol Cancer; 2021 May; 31(5):694-701. PubMed ID: 33741653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
    Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
    Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer.
    Lester-Coll NH; Young MR; Park HS; Ratner ES; Litkouhi B; Damast S
    Int J Gynecol Cancer; 2017 Nov; 27(9):1904-1911. PubMed ID: 28763364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
    Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
    Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Radical Hysterectomy for Clinically Apparent Stage II Endometrial Cancer Affect Risk of Local Recurrence?
    Lennox GK; Clark M; Zigras T; Rouzbahman M; Han G; Bernardini MQ; Gien LT
    J Obstet Gynaecol Can; 2021 May; 43(5):564-570. PubMed ID: 33412305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer.
    Montes de Oca MK; Albright BB; Secord AA; Havrilesky LJ; Moss HA
    Int J Gynecol Cancer; 2021 Dec; 31(12):1549-1556. PubMed ID: 34725205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
    Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
    J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
    Ma SK; Zhang HT; Sun YC; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma.
    Vance S; Yechieli R; Cogan C; Hanna R; Munkarah A; Elshaikh MA
    Gynecol Oncol; 2012 Jul; 126(1):16-9. PubMed ID: 22507535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of sentinel lymph node sampling versus traditional lymphadenectomy on the survival of patients with stage IIIC endometrial cancer.
    Nasioudis D; Byrne M; Ko EM; Giuntoli Ii RL; Haggerty AF; Cory L; Kim SH; Morgan MA; Latif NA
    Int J Gynecol Cancer; 2021 Jun; 31(6):840-845. PubMed ID: 33853879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
    Xiang M; English DP; Kidd EA
    Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.
    Lee JK; Ghanem AI; Modh A; Burmeister C; Mahmoud O; Maxwell GL; Elshaikh MA
    Brachytherapy; 2018; 17(2):319-325. PubMed ID: 29174935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment.
    Cosgrove CM; Cohn DE; Rhoades J; Felix AS
    Gynecol Oncol; 2019 Jun; 153(3):505-510. PubMed ID: 30935714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium.
    Nasioudis D; Roy AG; Ko EM; Cory L; Giuntoli Ii RL; Haggerty AF; Kim SH; Morgan MA; Latif NA
    Int J Gynecol Cancer; 2020 Aug; 30(8):1089-1094. PubMed ID: 32675056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement.
    Mariani A; Webb MJ; Keeney GL; Calori G; Podratz KC
    Gynecol Oncol; 2001 Oct; 83(1):72-80. PubMed ID: 11585416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
    Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
    Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.